AU2010282660B2 - Methods for iontophoretically treating nausea and migraine - Google Patents

Methods for iontophoretically treating nausea and migraine Download PDF

Info

Publication number
AU2010282660B2
AU2010282660B2 AU2010282660A AU2010282660A AU2010282660B2 AU 2010282660 B2 AU2010282660 B2 AU 2010282660B2 AU 2010282660 A AU2010282660 A AU 2010282660A AU 2010282660 A AU2010282660 A AU 2010282660A AU 2010282660 B2 AU2010282660 B2 AU 2010282660B2
Authority
AU
Australia
Prior art keywords
migraine
subject
hours
nausea
sumatriptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010282660A
Other languages
English (en)
Other versions
AU2010282660A1 (en
Inventor
Carol O'neill
Mark Pierce
Terri B. Sebree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of AU2010282660A1 publication Critical patent/AU2010282660A1/en
Application granted granted Critical
Publication of AU2010282660B2 publication Critical patent/AU2010282660B2/en
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH Request for Assignment Assignors: NUPATHE, INC.
Priority to AU2015230711A priority Critical patent/AU2015230711A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
AU2010282660A 2009-08-10 2010-08-10 Methods for iontophoretically treating nausea and migraine Ceased AU2010282660B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015230711A AU2015230711A1 (en) 2009-08-10 2015-09-22 Methods for iontophoretically treating nausea and migraine

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23261709P 2009-08-10 2009-08-10
US61/232,617 2009-08-10
US25679609P 2009-10-30 2009-10-30
US61/256,796 2009-10-30
US35830010P 2010-06-24 2010-06-24
US61/358,300 2010-06-24
PCT/US2010/045045 WO2011019732A1 (en) 2009-08-10 2010-08-10 Methods for iontophoretically treating nausea and migraine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015230711A Division AU2015230711A1 (en) 2009-08-10 2015-09-22 Methods for iontophoretically treating nausea and migraine

Publications (2)

Publication Number Publication Date
AU2010282660A1 AU2010282660A1 (en) 2012-03-08
AU2010282660B2 true AU2010282660B2 (en) 2015-06-25

Family

ID=43586432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010282660A Ceased AU2010282660B2 (en) 2009-08-10 2010-08-10 Methods for iontophoretically treating nausea and migraine

Country Status (11)

Country Link
US (2) US8845612B2 (enExample)
EP (1) EP2464234A4 (enExample)
JP (2) JP6116246B2 (enExample)
CN (3) CN105796533A (enExample)
AU (1) AU2010282660B2 (enExample)
BR (1) BR112012003111A8 (enExample)
CA (1) CA2770211A1 (enExample)
EA (1) EA201270227A1 (enExample)
IL (1) IL217935A0 (enExample)
NZ (1) NZ598622A (enExample)
WO (1) WO2011019732A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011019732A1 (en) 2009-08-10 2011-02-17 Nupathe, Inc. Methods for iontophoretically treating nausea and migraine
US9918932B2 (en) 2016-02-19 2018-03-20 Zosano Pharma Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4856188A (en) * 1984-10-12 1989-08-15 Drug Delivery Systems Inc. Method for making disposable and/or replenishable transdermal drug applicators
US5651768A (en) * 1983-08-18 1997-07-29 Drug Delivery Systems, Inc. Transdermal drug applicator and electrodes therefor
US5605536A (en) * 1983-08-18 1997-02-25 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5207752A (en) * 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
DE4014913C2 (de) * 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
JP3488466B2 (ja) * 1992-06-02 2004-01-19 アルザ・コーポレーション 電気駆動式薬物投与デバイス
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5458569A (en) * 1993-06-08 1995-10-17 Becton Dickinson And Company Wearable iontophoresis system
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
ATE211655T1 (de) * 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co Iontophoresematrix
US5697896A (en) * 1994-12-08 1997-12-16 Alza Corporation Electrotransport delivery device
IE960312A1 (en) * 1995-06-02 1996-12-11 Alza Corp An electrotransport delivery device with voltage boosting¹circuit
US6216033B1 (en) * 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
ATE263597T1 (de) * 1995-06-05 2004-04-15 Alza Corp Vorrichtung zur transdermalen iontophoretischen verabreichung von fentanyl und sufentanil
US6425892B2 (en) * 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5941843A (en) * 1996-07-12 1999-08-24 Empi, Inc. Iontophoresis electrode
US5882677A (en) * 1997-09-30 1999-03-16 Becton Dickinson And Company Iontophoretic patch with hydrogel reservoir
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
US6421561B1 (en) * 1999-12-30 2002-07-16 Birch Point Medical, Inc. Rate adjustable drug delivery system
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6653014B2 (en) * 2001-05-30 2003-11-25 Birch Point Medical, Inc. Power sources for iontophoretic drug delivery systems
WO2004002571A1 (en) * 2002-06-28 2004-01-08 Alza Corporation A reservoir for use in an electrotransport drug delivery device
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
RU2326893C2 (ru) * 2003-04-16 2008-06-20 Кориум Интернэшнл Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
US8734421B2 (en) * 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
US20050228336A1 (en) * 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US7856263B2 (en) * 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
AU2006297156A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoresis method and apparatus for systemic delivery of active agents
JP2009509685A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 損傷組織の治癒を増強するための血管新生因子の送達のためのイオントフォレーシス装置及び方法
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) * 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
WO2011019732A1 (en) 2009-08-10 2011-02-17 Nupathe, Inc. Methods for iontophoretically treating nausea and migraine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D3. Pierce MW "Headache relief" Drug Discovery and Development. 2008, Vol 11(3):pages 36-39. *

Also Published As

Publication number Publication date
CN105748401A (zh) 2016-07-13
JP2016014028A (ja) 2016-01-28
EA201270227A1 (ru) 2012-10-30
CA2770211A1 (en) 2011-02-17
IL217935A0 (en) 2012-03-29
US8845612B2 (en) 2014-09-30
CN105796533A (zh) 2016-07-27
AU2010282660A1 (en) 2012-03-08
CN102573489A (zh) 2012-07-11
EP2464234A4 (en) 2013-01-02
BR112012003111A8 (pt) 2017-10-10
WO2011019732A1 (en) 2011-02-17
JP6116246B2 (ja) 2017-04-19
US9592291B2 (en) 2017-03-14
JP2013501796A (ja) 2013-01-17
NZ598622A (en) 2014-02-28
BR112012003111A2 (pt) 2015-10-13
US20110066100A1 (en) 2011-03-17
EP2464234A1 (en) 2012-06-20
US20150032083A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
US9592291B2 (en) Methods for iontophoretically treating nausea and migraine
US8470853B2 (en) Transdermal methods and systems for the delivery of anti-migraine compounds
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US9427578B2 (en) Pharmacokinetics of iontophoretic sumatriptan administration
MX2007009968A (es) Metodo para una politerapia medicamentosa y combinaciones de medicamentos apropiadas para la misma.
KR101896441B1 (ko) 국소투여형의 연하장애 개선용 의약품
AU2015230711A1 (en) Methods for iontophoretically treating nausea and migraine
WO2024144678A1 (en) Orally disintegrating tablets (odt) formulations for the treatment of flu, common cold and allergic symptoms
AU2015203213B2 (en) Transdermal methods and systems for the delivery of anti-migraine compounds
KR20160018806A (ko) 연하장애 개선용 의약품
AU2012261753A1 (en) Transdermal methods and systems for the delivery of anti-migraine compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Free format text: FORMER APPLICANT(S): NUPATHE, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired